NCT02068846View on ClinicalTrials.gov

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
HIVSalivary Gland DiseaseBenign Lymphoepithelial Lesion
Interventions
DRUG

Ciprofloxacin

Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.

DRUG

Placebo

Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.

Trial Locations (1)

27599

The University of North Carolina School of Dentistry, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02068846 - BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent | Biotech Hunter | Biotech Hunter